MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-11-2026
Enlivex Therapeutics Ltd. Operating Income 2011-2026 | ENLV
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Enlivex Therapeutics Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -15 M | -15.9 M | -29.4 M | -25.8 M | -19.3 M | -9.78 M | -8.62 M | -5.3 M | -2.17 M | -15.9 M | -15.5 M | -7.08 M | -1.15 M | -226 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -226 K | -29.4 M | -12.2 M |
Quarterly Operating Income Enlivex Therapeutics Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | -3.81 M | - | - | - | -2.23 M | - | - | - | -1.3 M | - | - | - | - | - | - | - | - | - | -3.07 M | -4.58 M | -3.72 M | -4.49 M | -4.83 M | -3.59 M | -3.74 M | -3.32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.3 M | -4.83 M | -3.52 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
BioNTech SE
BNTX
|
15.3 B | $ 97.54 | 2.14 % | $ 27.2 B | Germany |
 |
Aligos Therapeutics
ALGS
|
-88 M | $ 8.65 | 8.19 % | $ 85.5 M |  USA |
 |
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | USA |
|
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Esperion Therapeutics
ESPR
|
60.3 M | $ 2.14 | -1.38 % | $ 445 M | USA |
 |
Evogene Ltd.
EVGN
|
-31 M | $ 0.81 | -0.07 % | $ 27.9 M |  Israel |
 |
Amphastar Pharmaceuticals
AMPH
|
140 M | $ 20.47 | 0.49 % | $ 957 M | USA |
 |
Genmab A/S
GMAB
|
2.64 B | $ 28.2 | -0.18 % | $ 18 B |  Danmark |
 |
Grifols, S.A.
GRFS
|
595 M | $ 8.19 | -0.24 % | $ 6.83 B |  Spain |
 |
GT Biopharma
GTBP
|
-12.4 M | $ 0.36 | -2.82 % | $ 1.98 M | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Halozyme Therapeutics
HALO
|
469 M | $ 67.06 | -1.12 % | $ 8.04 B | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
Harmony Biosciences Holdings
HRMY
|
208 M | $ 28.69 | -0.69 % | $ 1.65 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
23.5 M | $ 1.41 | 0.71 % | $ 363 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
-196 M | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 2.96 | 1.37 % | $ 4.87 M | Israel |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
-71.1 M | $ 4.16 | 1.84 % | $ 445 M | USA |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-12.2 M | $ 24.01 | -0.85 % | $ 3.05 B | USA |
 |
ImmuCell Corporation
ICCC
|
1.65 M | $ 7.12 | 1.14 % | $ 64.3 M | USA |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
-287 M | $ 32.24 | - | $ 2.14 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
-271 M | $ 1.48 | -0.67 % | $ 394 M | Britain |
|
Immatics N.V.
IMTX
|
-86.3 M | $ 10.48 | 0.43 % | $ 659 M | Germany |
 |
Cidara Therapeutics
CDTX
|
-176 M | - | - | $ 1.41 B | USA |
 |
Incyte Corporation
INCY
|
1.51 B | $ 94.86 | -1.26 % | $ 18.5 B | USA |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.61 | 2.35 % | $ 16.4 M | USA |
 |
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B | Britain |
 |
Inventiva S.A.
IVA
|
-52.1 M | $ 5.18 | -1.52 % | $ 138 M | France |